Back to search

Article

Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United States

2021-03-11

Abstract excerpt

<h4>Background: </h4> Lung cancer is the leading cause of cancer death in the United States. Among non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase mutation (ALK+) and who were resistant to crizotinib, ceritinib was approved as a following treatment. Ceritinib was found to be cost effective among Canadian patients, but its cost effectiveness among US population remains unknown. <h4>Objec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8ab472f4-6856-5bcc-b629-9a068e7c97a7
DOI
10.21203/rs.3.rs-264534/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cost effectiveness of ceritinib in patients previously treated with crizotinib and chemotherapy with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) in the United StatesDOI 10.21203/rs.3.rs-264534/v1
Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer.Semantic proximity
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness AnalysisSemantic proximity
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review.Semantic proximity
First-Line Pembrolizumab Plus Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness AnalysisSemantic proximity
Cost-Effectiveness of Sacituzumab Tirumotecan vs Chemotherapy for EGFR- TKI–Resistant NSCLC: Evidence to Inform Drug Pricing in the U.S. and ChinaSemantic proximity
Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review.Semantic proximity
Cost-effectiveness analysis of sacituzumab tirumotecan vs. chemotherapy for patients with EGFR-TKI-resistant, EGFR-mutated advanced non-small cell lung cancer in China.Semantic proximity
Camrelizumab In Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Cost-Effective Analysis In ChinaSemantic proximity
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.Semantic proximity
Cost-effectiveness analysis of Sacituzumab tirumotecan versus Platinum-based chemotherapy for EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC in ChinaSemantic proximity
Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.Semantic proximity
Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity
Select a neighboring publication to make it the new centre.